MS Speaks
Multiple Sclerosis => TREATMENTS => Topic started by: agate on October 12, 2018, 08:29:18 am
-
Presented at the 2018 ECTRIMS conference in Berlin (October 10-12)--"Cancer risk among Swedish multiple sclerosis patients: A nationwide cohort study comparing rituximab, fingolimod, and natalizumab":
http://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/293
Note: In the abstract, IR = Incidence Ratio
-
An article about these findings in Multiple Sclerosis News Today (October 12, 2018)--"Rituximab cancer risk in MS compared to Gilenya, Tysabri":
https://multiplesclerosisnewstoday.com/2018/10/11/ectrims2018-rituximab-cancer-risk-ms-compared-gilenya-tysabri/